Cargando…
Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs
BACKGROUND: In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resi...
Autores principales: | Arnaiz, Esther, Miar, Ana, Bridges, Esther, Prasad, Naveen, Hatch, Stephanie B., Ebner, Daniel, Lawrie, Charles H., Harris, Adrian L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344147/ https://www.ncbi.nlm.nih.gov/pubmed/34353313 http://dx.doi.org/10.1186/s12885-021-08616-8 |
Ejemplares similares
-
HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells
por: Moreno Roig, Eloy, et al.
Publicado: (2019) -
Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype
por: Nusblat, Leora M., et al.
Publicado: (2020) -
Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
por: Branco-Price, Cristina, et al.
Publicado: (2012) -
HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells
por: Arreola, Alexandra, et al.
Publicado: (2014) -
Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy
por: Davis, Leah, et al.
Publicado: (2022)